Topiramate Tablet, Film Coated
Product Images NDC 68071-4877

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68071-4877). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4877 3)

Label for Topiramate 100 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a 30-tablet package of film-coated tablets, each containing 100 mg of topiramate. It includes manufacturer information, product number P1813030, and instructions to store at controlled temperature 68-77°F. The label also contains barcode and lot details with a warning to keep out of reach of children.*

FDA Label Image

Structured Product Formula For Topiramate (971eaaa1 517d 455f B883 46210de3be3d 01)

Chemical structure of topiramate, showing its molecular arrangement with multiple rings, oxygen atoms, methyl groups, and a sulfonamide functional group.*

FDA Label Image

Structured Product Formula For Topiramate (971eaaa1 517d 455f B883 46210de3be3d 02)

A Kaplan-Meier survival curve chart depicting cumulative rates of time to first seizure for topiramate 50 mg/day and 400 mg/day dosages over approximately 500 days. The solid line represents 50 mg/day (N=234), and the dotted line represents 400 mg/day (N=236), showing higher cumulative seizure rates for the 50 mg/day group. A p-value of 0.0002 is indicated.*

FDA Label Image

Topiramate Tablets Usp (971eaaa1 517d 455f B883 46210de3be3d 03)

A bar graph illustrating the reduction in 4-week migraine headache frequency among adults and adolescents across two studies (Study 10 and Study 11). The x-axis shows different treatment groups: Placebo, Topiramate 50 mg/day, Topiramate 100 mg/day, and Topiramate 200 mg/day. The y-axis indicates the change from baseline to double-blind phase in average monthly migraine period rate, with reductions shown below zero. Bars display mean changes with standard error bars; Topiramate groups show greater reduction compared to Placebo, increasing with dosage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.